Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis

Objectives Cochrane reviews are currently of limited use as many healthcare professionals and patients have no access to them. Most member states of the Organisation for Economic Co-operation and Development (OECD) choose not to pay for nationwide access to the reviews, possibly uncertain whether th...

Full description

Bibliographic Details
Main Authors: Gerd Gigerenzer, Perke Jacobs
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/7/e033310.full
id doaj-a61eae85f86d4873bd7ef864b7b192cf
record_format Article
spelling doaj-a61eae85f86d4873bd7ef864b7b192cf2021-08-07T16:33:37ZengBMJ Publishing GroupBMJ Open2044-60552021-07-0111710.1136/bmjopen-2019-033310Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysisGerd Gigerenzer0Perke Jacobs1Harding Center for Risk Literacy, Max Planck Institute for Human Development, Berlin, GermanyHarding Center for Risk Literacy, Max Planck Institute for Human Development, Berlin, GermanyObjectives Cochrane reviews are currently of limited use as many healthcare professionals and patients have no access to them. Most member states of the Organisation for Economic Co-operation and Development (OECD) choose not to pay for nationwide access to the reviews, possibly uncertain whether there is enough demand to warrant the costs of a national subscription. This study estimates the demand for review downloads and summary views under free access across all OECD countries.Design The study employs a retrospective design in analysing observational data of web traffic to Cochrane websites in 2014. Specifically, we model for each country downloads of Cochrane reviews and views of online summaries as a function of free access status and alternative sources of variation across countries. The model is then used to estimate demand if a country with restricted access were to purchase free access. We use these estimates to perform a cost-benefit analysis.Results For one group of eight OECD countries, the additional downloads under free access are estimated to cost between US$4 and more than US$20 each. Three countries are expected to save money under free access, as existing institutional subscriptions would no longer be needed. For the largest group of 17 member states, free access is estimated to cost US$0.05–US$2 per additional review download. On average, the increase in review downloads does not appear to be associated with a decrease in the number of summary views. Instead, translations of plain-language summaries into national languages can serve as an additional strategy for dissemination.Conclusions We estimate that free access would cost less than US$2 per additional download for 20 of the 28 OECD countries without national subscriptions, including Canada, Germany and Israel. These countries may be encouraged by our findings to provide free access to their citizens.https://bmjopen.bmj.com/content/11/7/e033310.full
collection DOAJ
language English
format Article
sources DOAJ
author Gerd Gigerenzer
Perke Jacobs
spellingShingle Gerd Gigerenzer
Perke Jacobs
Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
BMJ Open
author_facet Gerd Gigerenzer
Perke Jacobs
author_sort Gerd Gigerenzer
title Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
title_short Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
title_full Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
title_fullStr Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
title_full_unstemmed Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost–benefit analysis
title_sort using variation between countries to estimate demand for cochrane reviews when access is free: a cost–benefit analysis
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2021-07-01
description Objectives Cochrane reviews are currently of limited use as many healthcare professionals and patients have no access to them. Most member states of the Organisation for Economic Co-operation and Development (OECD) choose not to pay for nationwide access to the reviews, possibly uncertain whether there is enough demand to warrant the costs of a national subscription. This study estimates the demand for review downloads and summary views under free access across all OECD countries.Design The study employs a retrospective design in analysing observational data of web traffic to Cochrane websites in 2014. Specifically, we model for each country downloads of Cochrane reviews and views of online summaries as a function of free access status and alternative sources of variation across countries. The model is then used to estimate demand if a country with restricted access were to purchase free access. We use these estimates to perform a cost-benefit analysis.Results For one group of eight OECD countries, the additional downloads under free access are estimated to cost between US$4 and more than US$20 each. Three countries are expected to save money under free access, as existing institutional subscriptions would no longer be needed. For the largest group of 17 member states, free access is estimated to cost US$0.05–US$2 per additional review download. On average, the increase in review downloads does not appear to be associated with a decrease in the number of summary views. Instead, translations of plain-language summaries into national languages can serve as an additional strategy for dissemination.Conclusions We estimate that free access would cost less than US$2 per additional download for 20 of the 28 OECD countries without national subscriptions, including Canada, Germany and Israel. These countries may be encouraged by our findings to provide free access to their citizens.
url https://bmjopen.bmj.com/content/11/7/e033310.full
work_keys_str_mv AT gerdgigerenzer usingvariationbetweencountriestoestimatedemandforcochranereviewswhenaccessisfreeacostbenefitanalysis
AT perkejacobs usingvariationbetweencountriestoestimatedemandforcochranereviewswhenaccessisfreeacostbenefitanalysis
_version_ 1721216979064324096